Catalio Capital Management Raises $381M Fund — Its Largest Yet

Published on : Published by : BioBuzz Media

Catalio Capital Management raises $381M fund — its largest yet
George Petrocheilos and R. Jacob Vogelstein are the managing partners of venture investment fund Catalio Capital Management LP.
Mark Dennis
By Matt Hooke – Reporter
May 03, 2022, 03:06pm EDT Updated 05/04/2022 10:31 am
See Correction/Clarification at end of article
Life sciences investment firm Catalio Capital Management has raised nearly $400 million for its next fund, its third and largest venture fund yet.
The company, which launched in 2020 after spinning out from Baltimore-based Camden Partners, raised $381 million to create its Nexus Fund III, Catalio announced Tuesday. That’s more than three times the $100 million co-founders George Petrocheilos and R. Jacob Vogelstein raised for the firm’s second fund in 2020. The company’s first fund in 2016, when it was still part of Camden Partners, raised $15 million.

Life Science Development Projects Position Baltimore BioMed Ecosystem for Boom

Published on : Published by : Steven Surdez

The Baltimore biotech ecosystem is thriving. And new, big and bold life sciences development projects are in the works, leading many to project Charm City as the next sector of the BioHealth Capital Region (BHCR) to boom.

BioHealth Capital Region Women Making Waves in Venture Capital

Published on : Published by : Steven Surdez

Improving access to venture capital for life science entrepreneurs and emerging biopharma companies in the BioHealth Capital Region (BHCR) is a top priority. However, elevating the region’s funding profile is not the only type of access undergoing a transformation in recent years.

Baltimore’s Personal Genome Diagnostics Secures $103 Million in Financing

Personal Genome Diagnostics Secures $103 Million in Financing
Published on : Published by : Alex Keown

Cancer genomics company Personal Genome Diagnostics Inc. (PGDx) secured $103 million in a Series C financing round. Proceeds from the financial infusion will be used to expand the company’s tissue-based and liquid biopsy portfolio and its global commercial footprint to support growth.